Cite
HARVARD Citation
Keystone, E. et al. (2013). THU0228 Tofacitinib, an Oral Janus Kinase Inhibitor: Post-HOC Analyses of Efficacy and Safety of Monotherapy Versus Combination Therapy in a Phase 3 Rheumatoid Arthritis Population. Annals of the rheumatic diseases. p. A242. [Online].